In this episode, we chat with David Harder, the Co-Founder and Co-CEO of ATMA Journey Centers, about their new healing and training space.
Similar Posts
MindMed Added to the FTSE!!! (Will MMED / MMEDF Stock Shoot UP?)
Hey guys! This is an impromptu video because I have some pretty cool MindMed News! MindMed is being added to the FTSE! Will mmed stock rocket up on Monday? How will MindMed’s addition to the FTSE will affect the stock and what even is the FTSE? These are all the topics we shall cover in this video.
I know we’re all impatiently waiting for MindMed to be uplisted on to the NASDAQ. But this MMED being added to the FTSE is also good news because it contributes to the company’s legitimacy! This is very goo new for MindMed and the mindmed stock price, at least in my opinion!
I hope this little impromptu episode added some life and joy to your live and that you guys found some value in this.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #MMEDNews
Interview With Yaron Conforti, Novamind
In this episode, Psychedelic Spotlights, Director of Content, Jill Ettinger sits down with Chief Executive Officer, Director, and Co-Founder of Novamind, Yaron Conforti.
Psychedelics Aiding Recovery with Arrowyn Ambrose
In this episode, Arrowyn speaks on how psychedelics are integrated into recovery and addiction, how community can profoundly impact those in recovery, and how we can assist those who are in need of psychedelic therapy but may not have access.
More MindMed Catalysts: MMED MMEDF Stock Opportunity (Plus Jr & Kevin O’Leary comments)
Today we’ll discuss More MindMed Catalysts: MMED MMEDF Stock Opportunity (Plus Jr & Kevin O’Leary comments)
Today’s episode is a short follow up video to our last episode, where we looked at the catalysts for MindMed and MindMed stock in 2021.
We have already covered the NASDAQ uplisting, Clinical trial updates that MindMed will give this year and Conference calls and possible financing deals. But of course, we missed a few of important possible catalysts, as you guys so rightly pointed out.
So in this episode we are briefly going to run through them.
So what else can MindMed and MMED/MMEDF investors expect this year?
1. The imminent launch of the first Psychedelic Medicines ETF, The North American Psychedelics Index (PSYK)
-When will it launch?
-In what manner will it affect MindMed
-And how much it will influence MindMed’s stock price
2. Atai Life Sciences expected IPO how that’ll affect MindMed
– How will the IPO of another big rival will affect MMED/MMEDF?
3. Potential catalyst of Partnerships, Mergers and Acquisitions
-Coming directly from an Interview with JR Rahn and Kevin O’Leary
Unlike the 1st two catalysts we discuss here, as well as a potential Nasdaq uplisting, future partnerships mergers and acquisitions would affect MindMed’s long term value, and their ability to develop, produce and distribute game changing medicines.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://mindmed.co/news/press-release/mindmed-expands-psychedelic-microdosing-division-adds-groundbreaking-study-evaluating-lsd-microdosing-through-next-gen-digital-clinical-markers/
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMED #MMEDF
The PROBLEM With Psilocybin – How Is BRIGHT MINDS Fixing That? (DRUG/BMBIF)
The PROBLEM With Psilocybin – How Is BRIGHT MINDS Fixing That? (DRUG/BMBIF)
In the interview we discuss most of Bright Minds’ major projects, including using new psychedelic medicines to treat chronic pain. This is exciting, since it could not only help people with chronic pain issues such as fibromyalgia, but it could also put a dent in the opioid use crisis by preventing people from being prescribed opioids by their doctors to treat pain.
I had a blast in this interview, and I know you will find it fascinating! Enjoy!
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor, Psychedelic Spotlight, and a third party. The Psychedelic Investor has been hired for a period beginning on 28,09,2021 and ending on 29,09,2021 to publicly disseminate information about (BRIGHT MINDS BIOSCIENCE INC) via digital communications. We have been paid ($2000 CAD).
#BrightMinds #PsychedelicStocks #Psilocybin
MindMed Launches DMT Clinical Trial (Joe Rogan Must Be Excited for MNMD)
MindMed Launches DMT Clinical Trial! Joe Rogan must be excited!
In this episode, we’ll discuss MindMed ‘s (NASDAQ: MNMD), ( NEO: MMED) announcement and why I’m personally excited about it.
As many of you know, of all the classic psychedelics, in many respects DMT, or dimethyltryptamine, is the most mysterious. When it is consumed, experiencers report being blasted off into an entirely new dimension of being or plane of existence, where you interact with autonomous, intelligent and wise beings. Those who have experienced this often claim that they return to our world with a sense of having learned important lessons, that are either too hard to put into words.
Now, we have no idea what is happening in a person’s brain while they are on DMT.
Is the experience completely physiological, for example has the DMT essentially initiated some sort of dream-like state while you are still conscious? Or is it more mystical than that?
Either way, the simplistic wisdom gained from “the spirit molecule”, as it is often called, has reportedly helped countless people beat their addictions, depression, anxiety and more.
Many people liken it to essentially “resetting your brain”.
Unfortunately, despite so much anecdotal evidence and entire sub cultures verging on the edge of religions dedicated to the substance, surprisingly little hard science has been done on the drug.
This is the reason behind my excitement today! MindMed announced initiation of phase 1 clinical trial of intravenous DMT.
Links:
MINDMED ANNOUNCES INITIATION OF PHASE 1 CLINICAL TRIAL OF INTRAVENOUS DMT:
https://thepsychedelicinvestor.com/2021/07/28/mindmed-announces-initiation-of-phase-1-clinical-trial-of-intravenous-dmt/
MindMed’s DMT Clinical Trial Specifications:
https://clinicaltrials.gov/ct2/show/NCT04353024?term=DMT&draw=2&rank=2
Previous DMT Studies:
https://www.nature.com/articles/s41598-020-61169-x
https://maps.org/research-archive/ayahuasca/Thomas_et_al_CDAR.pdf
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #DMT #MNMD